These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33587338)

  • 1. Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies.
    Mondal T; Shivange GN; Tihagam RG; Lyerly E; Battista M; Talwar D; Mosavian R; Urbanek K; Rashid NS; Harrell JC; Bos PD; Stelow EB; Stack MS; Bhatnagar S; Tushir-Singh J
    EMBO Mol Med; 2021 Mar; 13(3):e12716. PubMed ID: 33587338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.
    Zhou Y; Liang Z; Xia Y; Li S; Liang J; Hu Z; Tang C; Zhao Q; Gong Q; Ouyang Y
    Chem Biol Interact; 2023 Jan; 369():110260. PubMed ID: 36414028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.
    Liu WL; Zhang YQ; Luo XJ; Zhu YY; Song L; Ming ZH; Zhang LX; Li MJ; Lv RC; Zhang GJ; Chen M
    Int J Nanomedicine; 2023; 18():5141-5157. PubMed ID: 37705867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 5. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
    Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
    Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
    Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
    Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
    J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.
    Chen C; Li S; Xue J; Qi M; Liu X; Huang Y; Hu J; Dong H; Ling K
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.
    Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L
    Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
    Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
    Front Immunol; 2018; 9():2140. PubMed ID: 30294328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
    Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
    Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
    Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
    Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
    Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer.
    Zhang J; Zhang G; Zhang W; Bai L; Wang L; Li T; Yan L; Xu Y; Chen D; Gao W; Gao C; Chen C; Ren M; Jiao Y; Qin H; Sun Y; Zhi L; Qi Y; Zhao J; Liu Q; Liu H; Wang Y
    Cell Death Differ; 2022 Nov; 29(11):2247-2261. PubMed ID: 35538152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
    Lee JV; Housley F; Yau C; Nakagawa R; Winkler J; Anttila JM; Munne PM; Savelius M; Houlahan KE; Van de Mark D; Hemmati G; Hernandez GA; Zhang Y; Samson S; Baas C; Kok M; Esserman LJ; van 't Veer LJ; Rugo HS; Curtis C; Klefström J; Matloubian M; Goga A
    Nat Commun; 2022 Jun; 13(1):3671. PubMed ID: 35760778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
    Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
    Lotfinejad P; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Jadidi Niaragh F; Safaei S; Asadi M; Baradaran B
    Life Sci; 2020 Oct; 259():118297. PubMed ID: 32822718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed cell death ligand - 1 expression in triple negative breast carcinoma and its prognostic significance in Indian population.
    Gajaria PK; Gupta MR; Patil A; Desai SB; Shet TM
    Indian J Pathol Microbiol; 2021; 64(4):664-670. PubMed ID: 34673583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.